On September 29, 2020 PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, reported the closing of its initial public offering of 13,529,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares of common stock, at a public offering price of $18.00 per share (Press release, PMV Pharma, SEP 29, 2020, View Source [SID1234567731]). The aggregate gross proceeds to PMV Pharma from the offering were approximately $243.5 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by PMV Pharma. PMV Pharma’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol "PMVP."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC, BofA Securities, Cowen and Evercore ISI acted as joint book-running managers for the offering.

A registration statement relating to the shares sold in the offering was filed with the Securities and Exchange Commission and became effective on September 24, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus, when available, may be obtained for free from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at [email protected]; BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255, or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at 1-833-297-2926, or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at 1-888-474-0200, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On September 29, 2020 IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) reported financial results for its fiscal year 2021 first quarter ended July 31, 2020 (Press release, ImmunoPrecise Antibodies, SEP 29, 2020, View Source [SID1234567730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q1 Fiscal 2021 Financial Highlights:

• Revenue increases by $1.1 million, or 39%, to $3.8 million versus $2.7 million for Q1 2020
• Gross profit increases by $1.1 million to 64% of revenue vs 51% of revenue for the prior year period.
• Adjusted EBITDA increases to $932,000 compared to a loss of $481, 000 for the same period last year.
• Cash on hand is $6.0 million as of July 31, 2020.
• Warrants exercised after quarter-end through September 28, 2020 provide $9.7 million in cash in exchange for 7.8 million shares of stock, all warrants expiring September 24, 2020 were exercised.

Financial Results

Revenue. The Company achieved revenues of $3,764,977 during the three months ended July 31, 2020, compared to revenues of $2,716,099 during the same quarter in 2019. This represents a 39% increase in revenue for the period. The increasing revenue trend is due to increases in both volume and financial value of client contracts as a result of continued focus on expanding the breadth and depth of services offered, new client onboarding including top pharma companies, and growing its core existing client business.

Gross Margin. During the three months ended July 31, 2020, the Company achieved a gross profit of $2,410,326, compared to $1,376,406 in 2019. This represents a 64% increase compared to 51% for the same period last year.

Net Loss. The Company recorded a net loss of $549,318 during the three months ended July 31, 2020, compared to net loss of $2,012,198 for the three months ended July 31, 2019, primarily due to higher revenue and gross profit as well as an increase in Other Income as a result of research grant awards and government subsidies.

Non-IFRS Measures. * Adjusted EBITDA for the three months ended July 31, 2020 was $932,716 compared to ($481,499) for same period last year. This significant improvement in Adjusted EBITDA is primarily a result of the increase in gross profit and research grant awards and government subsidies.

Warrant Exercises. During the first quarter, 3,305,500 warrants were exercised issuing shares of common stock for $3,566,474 in cash. Subsequent to quarter-end, 7,813,000 warrants were exercised issuing shares of common stock for $9,725,000 in cash. All warrants expiring September 24, 2020 were exercised.

Dr. Jennifer Bath, CEO and President of ImmunoPrecise, commented, "This has been a transformative quarter, both financially and operationally. We achieved solid revenues, as we added new clients and expanded services with our existing clients. As a result, we achieved positive adjusted EBITDA and cash flow from operations. At the same time, we have further strengthened our balance sheet and enhanced our capital structure through the exercise of warrants, providing the opportunity to generate more intellectual property assets."

"Operationally, we continue to make tremendous progress, advancing programs both with our clients as well as our proprietary COVID-19 programs. We recently announced an important research collaboration with Zymeworks Inc., providing us access to their Zymeworks’ Azymetric and EFECT platforms for the further development of multiple antibody candidates to fight COVID-19. Most recently, we announced the initiation of pre-clinical vaccine trials against SARS-CoV-2 together with LiteVax BV (Oss, the Netherlands). Overall, we are rapidly advancing our Polytope Therapy and Vaccine programs, which we believe represent the most comprehensive and diverse antibody cocktail approach globally."

"Given our financial and operational progress, we felt this was the appropriate time to commence our NASDAQ listing process. As the world’s pre-eminent exchange for biotech and pharma companies, we believe a NASDAQ listing will provide us greater exposure within the investment community as we execute on key upcoming milestones."

IPA periodically provides information for investors on its corporate website, www.immunoprecise.com. This includes press releases and other information on financial performance, reports filed or furnished with the TSX, information on corporate governance and details related to its annual meeting of shareholders. Reports filed or furnished with the TSX can be found at www.sedar.com.

On September 29, 2020 TriSalus Life Sciences (TriSalus), an emerging immuno-oncology Company committed to transforming outcomes for patients with solid tumors, reported the appointment of Steven Katz, M.D., as its Chief Medical Officer (Press release, TriSalus Life Sciences, SEP 29, 2020, View Source [SID1234567729]). Katz will oversee the Company’s clinical development strategy as it seeks to overcome poor outcomes in the treatment of solid tumors by combining TriSalus’ proprietary, FDA-cleared intravascular, regional drug delivery technology with immuno-oncology therapeutics. Katz has served as the Company’s Chief Medical Advisor and as Chairman of its Scientific Advisory Board since 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mary Szela, Chief Executive Officer and President of TriSalus Life Sciences, said, "We are thrilled to have Steven join TriSalus as a member of our leadership team and one who will advance our goal of improving outcomes for patients with solid pancreatic and liver tumors. Steven’s scientific acumen and clinical experience are second to none, but it’s his relentless commitment to eradicating solid tumors by embracing new approaches that will make the most lasting impact on overcoming one of the greatest challenges in cancer care."

Steven Katz, M.D., Chief Medical Officer of TriSalus Life Sciences, said, "Joining TriSalus will allow me to leverage my experiences as a surgeon, clinician and scientist to realize my ultimate goal – transforming outcomes for solid tumor patients with metastatic disease. New therapies are improving the way in which we treat cancer, but critical barriers in solid tumors prevent optimal delivery and performance of therapeutics."

"I can’t wait to continue our work as a member of the TriSalus team. We’re focused on integrating delivery technology that can deliver therapeutic directly to the site of disease with therapeutic agents that both kill cancer cells and stimulate the body’s immune system in the fight. Through our relationships with exceptional academic clinical sites, we can rapidly initiate and execute clinical trials using this novel approach."

Katz attended the New York University School of Medicine, receiving the Alpha Omega Alpha Award. He completed his general surgery residency at the New York University Medical Center. Dr. Katz completed Fellowships in Immunology and Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. Katz maintains a part-time clinical practice focused on liver tumors, pancreas cancer, sarcoma, and melanoma. His laboratory research endeavors focus on immunotherapy for solid tumor metastases and he has led a cGMP cell therapy facility. He has served as the principal investigator for five solid tumor CAR-T trials, including four for liver metastases and one for peritoneal carcinomatosis. Dr. Katz has invented numerous cell therapy products and methods currently under testing or development.

TriSalus was formed to investigate treatments to help stimulate the immune system to overcome immunosuppression by delivering a combination of immuno-oncology therapies directly to the site of disease. We are researching this multi-pronged approach to reprogram the immunosuppressive tumor microenvironment, harness the power of tumor killing agents, and deliver these therapies directly to the tumor through its Pressure-Enabled Drug Delivery (PEDD) approach. The Company has identified validated, IND-ready targets to acquire through license agreements, collaborations, or joint ventures. TriSalus is initially focused on the goal of successfully treating intractable solid tumors including uveal melanoma liver metastases and pancreatic cancer.

About SD-101

TriSalus recently acquired SD-101, an investigational Toll-Like receptor 9 (TLR9) agonist that has been tested in Phase 2 clinical trials for advanced cutaneous melanoma and head and neck cancer, evaluating efficacy, safety, and the ability to increase responsiveness to checkpoint inhibitors in PD-L1 negative tumors.

By combining SD-101 with TriSalus’ proprietary FDA cleared, drug delivery technologies, TriSalus will deliver the agent into the local vasculature of solid tumors. The Company intends to begin evaluating SD-101 in patients with uveal melanoma liver metastases followed by testing in patients with pancreatic ductal adenocarcinoma and colorectal cancer liver metastases. In addition, a separate program for locally advanced pancreatic ductal adenocarcinoma is in progress.

SD-101 is an investigational proprietary short sequence of synthetic deoxyribonucleic acid (DNA) which binds to the Toll-Like receptor 9 (TLR9) found on suppressive immune cells including myeloid-derived suppressor cells and antigen presenting cells.1 SD-101 has been evaluated in numerous clinical studies to assess safety and efficacy. Investigational studies suggest responsiveness to checkpoint inhibitors in PD-L1 negative tumors as well as inducing an influx of cytotoxic T cells and interferon gamma production.2

SD-101 will be evaluated in multiple visceral organ tumor types to assess its safety and activity via PEDD as well as in combination with other immunotherapies and modalities. For more information on SD-101 clinical trials that are currently recruiting patients, please visit www.clinicaltrials.gov.

About Pressure-Enabled Drug Delivery (PEDD)
Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology features a self-expanding, nonocclusive, one-way valve which can infuse therapeutics into solid tumor vasculature.3 The FDA cleared SmartValve devices have been shown to deliver more therapy into the tumor while preventing embolic reflux.4

On September 29, 2020 VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, reported Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, in a format of a fireside chat with analyst Geulah Livshits, PhD, at the Chardan 4th Annual Genetic Medicines Conference, to be held virtually October 5-6 2020 (Press release, VBL Therapeutics, SEP 29, 2020, View Source [SID1234567728]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Date: Tuesday, October 6th
Time: 9:00AM Eastern Time.
Webcast: Link
An archive recording will be available for listening after the event, on the Investor Relations page of VBL’s corporate website, under "Events & Presentations."

On September 29, 2020 Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, reported that it has signed a license agreement with the National Cancer Institute (NCI) for the commercialization of mesothelin-targeting agents (Press release, Navrogen, SEP 29, 2020, View Source [SID1234567727]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mesothelin is a cell surface protein that is over-expressed on a number of cancer types. Previous studies have found that certain therapeutic antibodies, which use humoral immune function for target cell killing, as well as antibody-drug conjugates (ADC) targeting mesothelin are negatively affected by factors produced in the tumor microenvironment. Navrogen has employed its proprietary Humoral Immuno Oncology (HIO) technology to screen for anti-mesothelin antibodies that are refractory to tumor-produced, immuno-suppressive factors from multiple sources and identified an anti-mesothelin antibody from the NCI collection. Navrogen has reformatted the antibody using next gen technologies and is advancing it into preclinical studies against a wide range of mesothelin-expressing cancers.

"We are pleased to obtain this commercial license from the NCI" said Dr. Nicholas Nicolaides, PhD, President and Chief Executive Officer of Navrogen. "Our team’s experience with this target will enable us to make key development decisions to maximize the opportunity for clinical success and offer patients with mesothelin-expressing cancers new therapeutic options."

Dr. Luigi Grasso, Chief Scientific Officer of Navrogen added, "We were delighted to identify an anti-mesothelin antibody that can naturally avoid the humoral immuno-suppressive effects caused by certain tumor-produced proteins. Our work with this antibody has shown positive activity across some of the more aggressive preclinical models tested. We look forward to expanding upon these preliminary findings and sharing our results with the oncology community in the near future."